LONGEVA.

Tirzepatide: Side Effects Reported in Studies

This page collects the adverse effects of tirzepatide that the authors of published studies described. The review rests on randomized clinical trials in adults with obesity or type 2 diabetes and on meta-analyses of those trials. It is reference material on what the literature reported, not advice on use. SURMOUNT-1 and SURPASS-4 studied subcutaneous clinical tirzepatide [1][5]. Reported frequencies concern the respective study populations and conditions and do not establish risks for a particular marketed lyophilizate or batch. A recorded adverse event is not necessarily a drug-caused adverse reaction.

Summary

  • Gastrointestinal effects (nausea, diarrhea, vomiting) were reported most often. The authors described them mostly as mild to moderate [1][4][5]; they occurred mainly during dose escalation [1][5].
  • Within the ten-study meta-analysis, pooled gastrointestinal event estimates from the three studies contributing this outcome were 39%, 46% and 49% at 5, 10 and 15 mg, respectively [8].
  • Pooled point estimates for severe hypoglycemia, acute pancreatitis and cholecystitis in that meta-analysis did not exceed 1%; fatal-event estimates were 0.72-1.07% [8]. These are estimates, not risk ceilings or confirmed causal reactions. A meta-analysis of 12 RCTs found higher relative risk of gallbladder and biliary disease than in controls [9].

What the studies reported

EffectModel or participantsHow often or as describedSource
Nausea, diarrhea, vomitingAdults with type 2 diabetes, 40 weeks, versus placeboNausea 12-18% vs 6%, diarrhea 12-14% vs 8%, vomiting 2-6% vs 2%[3]
Nausea, diarrhea, vomitingAdults with type 2 diabetes; tirzepatide 5, 10 or 15 mg versus semaglutide 1 mg; 40 weeksNausea 17-22% vs 18%, diarrhea 13-16% vs 12%, vomiting 6-10% vs 8%[4]
Nausea, diarrhea, decreased appetite, vomitingType 2 diabetes with increased cardiovascular risk, versus insulin glargine, full study period, 52 to 104 weeksNausea 12-23%, diarrhea 13-22%, decreased appetite 9-11%, vomiting 5-9%; glargine 2%, 4%, under 1% and 2%[5]
Gastrointestinal events overallReview of 10 studies, 6836 participants; this outcome: three-study subsetPooled point estimates: 39% (5 mg), 46% (10 mg), 49% (15 mg)[8]
Nausea, vomiting, diarrhea versus placeboMeta-analysis of 7 type 2 diabetes trials, 6609 participantsAt 15 mg, odds ratios: nausea 5.60, vomiting 5.50, diarrhea 3.31[7]
Hypoglycemia below 54 mg/dLSURPASS-2: adults with type 2 diabetes, versus semaglutide 1 mg, 40 weeks0.6% (5 mg), 0.2% (10 mg), 1.7% (15 mg) vs 0.4% with semaglutide[4]
Hypoglycemia below 54 mg/dL or severeType 2 diabetes, versus glargine6-9% vs 19%; without sulfonylurea 1-3% vs 16%[5]
Gallbladder and biliary diseaseMeta-analysis of 12 RCTs, 12,351 participantsRelative risk 1.52 (95% CI 1.17-1.98); cholelithiasis 1.67 (1.14-2.44)[9]
Discontinuation because of adverse eventsObesity without diabetes, 72 weeks4.3%, 7.1% and 6.2% at 5, 10 and 15 mg vs 2.6% with placebo[1]

What the effects depended on

The SURMOUNT-1 authors noted that gastrointestinal events occurred mainly during the dose-escalation period [1]. In the ten-study meta-analysis, pooled gastrointestinal estimates from the three studies contributing this outcome rose with dose. The numerically highest pooled discontinuation estimate was about 10% at 15 mg, but a statistically clear difference in this endpoint across doses was not established [8]. Another meta-analysis found higher odds of adverse-event discontinuation at 15 mg versus placebo and GLP-1 receptor agonists; these are separate comparator-specific findings [7]. The dose schedules used in the studies are described in the tirzepatide dosing reference.

Serious and rare events

In the ten-study meta-analysis, pooled point estimates for severe hypoglycemia, acute pancreatitis, cholelithiasis and cholecystitis did not exceed 1% at each dose. Fatal-event estimates were 0.72-1.07%; these are not risk ceilings or proof that tirzepatide caused the deaths [8]. For the glucose ≤70 mg/dL threshold in Table 2, the numerically highest pooled estimate was at 10 mg: 22.6%; a dose difference was not established [8]. In SURMOUNT-2 (obesity with type 2 diabetes), serious adverse events were recorded in 68 of 938 participants (7%) across all three groups combined, including placebo. Two deaths occurred in the tirzepatide 10 mg group; investigators did not consider them related to study treatment [2]. In SURPASS-4, serious cardiovascular events were not more frequent than with insulin (hazard ratio 0.74; 95% CI 0.51-1.08) [5]. The Cochrane review included 9 trials with 7111 adults with obesity overall. In placebo comparisons at 12-18 months, tirzepatide may increase non-serious adverse events (RR 1.33; 95% CI 1.03-1.71; 5 studies, 4582 participants; low-certainty evidence). Evidence on serious events was very uncertain (RR 0.99; 95% CI 0.88-1.12; 8 studies, 6359 participants; very low certainty) [10]. Gallbladder and biliary tract: according to a meta-analysis of 12 RCTs, the risk of related events in tirzepatide groups was higher than in controls, with no clear dose relationship [9].

Limits of the evidence

Most data come from registration trials lasting 40 to 104 weeks; all nine trials in the Cochrane review reported a major role of the manufacturer in design, conduct, analysis or writing [10]. Meta-analyses pool different populations (obesity, type 2 diabetes), so frequencies from different sources are not always comparable. Frequencies in the table are given as the authors reported them and depend on trial design and how events were recorded. Data on longer follow-up are limited: the Cochrane review summarised one study of about 3.5 years, with very low certainty for serious events [10].

FAQ

Which tirzepatide side effects are described most often?

Clinical trials most often reported gastrointestinal effects: nausea, diarrhea, vomiting and decreased appetite. In SURPASS-4, for example, nausea occurred in 12-23% of participants, diarrhea in 13-22% and vomiting in 5-9%, and the authors described most cases as mild to moderate and arising during dose escalation [5]. Within the ten-study meta-analysis, pooled gastrointestinal event estimates were 39-49% depending on dose; three studies contributed this outcome [8].

Do side effects depend on the dose?

For gastrointestinal events, pooled estimates from three studies within the ten-study meta-analysis rose from 39% at 5 mg to 49% at 15 mg. The numerically highest discontinuation estimate was at 15 mg, about 10%, but a statistically clear difference in this endpoint across doses was not established [8]. Another meta-analysis compared doses with placebo and also described higher odds of nausea, vomiting and diarrhea at 15 mg [7]. The dose schedules from the studies are collected in a separate dosing reference.

Is tirzepatide linked to gallbladder problems?

In a meta-analysis of 12 randomized trials (12,351 participants), tirzepatide was associated with gallbladder and biliary disease (relative risk 1.52; 95% CI 1.17-1.98) and with cholelithiasis (1.67; 1.14-2.44), with no clear dose relationship [9]. The authors stressed that this signal needs further study in post-marketing data. In another meta-analysis, pooled point estimates for acute pancreatitis, cholelithiasis and cholecystitis did not exceed 1%; these are not risk ceilings [8].

What did studies show after tirzepatide was stopped?

In SURMOUNT-4, participants first received tirzepatide for 36 weeks and were then randomized to continue or to switch to placebo. The placebo group regained part of the lost weight: the weight change from week 36 to week 88 was +14.0% versus -5.5% in those who continued [6]. This result concerns weight rather than safety, but the trial describes what happened after withdrawal.

See also: all side-effects references, tirzepatide monograph, product page.

References

  1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. https://doi.org/10.1056/NEJMoa2206038
  2. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613-626. https://doi.org/10.1016/S0140-6736(23)01200-X
  3. Rosenstock J, Wysham C, Frias JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143-155. https://doi.org/10.1016/S0140-6736(21)01324-6
  4. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515. https://doi.org/10.1056/NEJMoa2107519
  5. Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811-1824. https://doi.org/10.1016/S0140-6736(21)02188-7
  6. Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38-48. https://doi.org/10.1001/jama.2023.24945
  7. Karagiannis T, Avgerinos I, Liakos A, et al. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022;65(8):1251-1261. https://doi.org/10.1007/s00125-022-05715-4
  8. Mishra R, Raj R, Elshimy G, et al. Adverse events related to tirzepatide. J Endocr Soc. 2023;7(4):bvad016. https://doi.org/10.1210/jendso/bvad016
  9. Gong J, Gao F, Jiang K, et al. Risk of biliary diseases in patients with type 2 diabetes or obesity treated with tirzepatide: a meta-analysis. J Diabetes Investig. 2025;16(1):83-92. https://doi.org/10.1111/jdi.14340
  10. Franco JVA, Guo Y, Varela LB, et al. Tirzepatide for adults living with obesity. Cochrane Database Syst Rev. 2025;(10):CD016018. https://doi.org/10.1002/14651858.CD016018